期刊文献+

新型酪氨酸激酶抑制剂的合成及其活性评价

Synthesis and activity evaluation of novel tyrosine kinase inhibitors
下载PDF
导出
摘要 目的以L029为先导化合物,设计合成具有蛋白酪氨酸激酶(PTK)抑制活性的化合物。方法以L029为原料,通过还原和(或)在其活泼H等位点接入侧链3-二甲基氨基-1-丙烷、乙酸甲酯、丙酸甲酯等基团,设计合成了一系列L029衍生物,并用酶联免疫吸附法(ELISA)测定其PTK活性,计算抑制率。结果成功合成5个目标化合物,结构经1H NMR和MS确证。其中3个化合物T2、T3、T5具有较强的PTK抑制活性。结论本文研究的目标化合物合成路线方法简单,反应条件温和,3个目标化合物具有较强PTK抑制活性,为进一步开展此类分子的设计合成提供了参考。 Objective To design and synthesize compounds with protein tyrosine kinase(PTK)inhibitory activity with L029 as the lead compound. Methods L029 derivatives were designed and synthesized from L029 by reduction and/or substitution with the3-dimethylamino-1-propyl,methyl acetate,methyl propionate in its active H and other sites. PTK activity was measured by enzymelinked immunosorbent assay(ELISA). The inhibitory rate was calculated to screen out the compounds with PTK inhibitory activity. Results Five target compounds were synthesized and their structures were confirmed by1 H NMR and MS. Three compounds T2,T3 and T5 were screened out with strong PTK inhibitory activity. Conclusion The synthetic routes of the target compounds are simple with mild reaction condition,and 3 compounds show strong inhibitory activity by ELISA. These results can provide reference for the further design and synthesis of this kind of molecules.
作者 杨宏鹏 王刚 彭涛 温晓雪 杨建云 孙云波 刘曙晨 张首国 王林 YANG Hong-peng WANG Gang PENG Tao WEN Xiao-xue YANG Jian-yun SUN Yun-bo LIU Shu-chen ZHANG Shou-guo WANG Lin(Anhui Medical University, Hefei 230032, China Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China)
出处 《国际药学研究杂志》 CSCD 北大核心 2017年第6期575-579,共5页 Journal of International Pharmaceutical Research
基金 国家自然科学基金资助项目(81273431 21102176)
关键词 蛋白酪氨酸激酶抑制剂 设计合成 L029 protein tyrosine kinase inhibitor design and synthesis L029
  • 相关文献

参考文献4

二级参考文献112

  • 1许治良,高虹,欧阳克清,郑旭煦,蔡昭皙,胡应和.G-蛋白偶联受体的功能测定和高通量药物筛选[J].中国药理学通报,2003,19(12):1330-1365. 被引量:12
  • 2Jimeno A,Hidalgo M.Multitargeted therapy:can promiscuity be praised in an era of political correctness?[J].Crit Rev Oncol Hematol,2006,59(2):150-158.
  • 3De Jonge MJ,Verweij J.Multiple targeted tyrosine kinase inhibition in the clinic:all for one or one for all?[J].Eur J Cancer,2006,42(10):1351-1356.
  • 4Keith CT,Borisy AA,Stockwell BR.Multicomponent therapeutics for networked systems[J].Nat Rev Drug Discov,2005,4(1):71-78.
  • 5Arora A,Scholar EM.Role of tyrosine kinase inhibitors in cancer therapy[J].J Pharmacol Exp Ther,2005,315(3):971-979.
  • 6Blume-Jensen P,Hunter T.Oncogenic kinase signalling[J].Nature,2001,411(6835):355-365.
  • 7Konecny GE,Pegram MD,Venkatesan N,et al.Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells[J].Cancer Res,2006,66(3):1630-1639.
  • 8Burris HA,Hurwitz HI,Dees EC,et al.Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinib (GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[J].J Clin Oncol,2005,23(23):5305-5313.
  • 9Hanrahan EO,Heymach JV.Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer[J].Clin Cancer Res,2007,13(15):4617-4622.
  • 10Arnold AM,Seymour L,Smylie M,et al.Phase Ⅱ study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy:National Cancer Institute of Canada Clinical Trials Group Study BR.20[J].J Clin Oncol,2007,25(27):4278-4284.

共引文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部